Literature DB >> 3301209

Conjunctival lesions in adults. A clinical and histopathologic review.

H E Grossniklaus, W R Green, M Luckenbach, C C Chan.   

Abstract

A total of 2,455 conjunctival lesions in adults (over 15 years old) obtained during a 61-year period were reviewed and histopathologically classified as congenital, acquired epithelial, acquired subepithelial, pigmented, inflammatory/degenerative, and miscellaneous. The most common lesions in decreasing order of frequency were: pterygium, nevus, dysplasia, nonspecific nongranulomatous inflammation, and epithelial inclusion cyst. The most common conjunctival malignancy in adults was squamous cell carcinoma, followed by melanoma, and pagetoid change associated with sebaceous gland carcinoma. Squamous cell carcinomas arise from progressive stages of mild, moderate, and severe dysplasia. These tumors have a low malignant potential but may behave more aggressively in the spindle cell and mucoepidermoid variants. Melanomas arise de novo, from nevi or, most commonly, from acquired melanosis and have an associated 14-32% mortality rate by metastatic spread. Sebaceous carcinomas are often initially clinically misdiagnosed, involve the conjunctiva by pagetoid spread, and can have a low rate of metastasis and death if diagnosed early and excised with frozen-section monitoring of the surgical margins.

Entities:  

Mesh:

Year:  1987        PMID: 3301209     DOI: 10.1097/00003226-198706020-00002

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  75 in total

1.  Indeterminate melanocytic proliferations of the conjunctiva.

Authors:  H E Grossniklaus; C E Margo; A R Solomon
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Primary Acquired Melanosis: Clinical, Histopathologic and Optical Coherence Tomographic Correlation.

Authors:  Yahya A Alzahrani; Smita Kumar; Hassan Abdul Aziz; Thomas Plesec; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2015-11-12

3.  Primary mantle cell lymphoma of the conjunctiva: a case report.

Authors:  Miltiadis Aspiotis; Spiridon Gorezis; Ioannis Asproudis; Elena Tsanou; Evangelos Papadiotis; Sevasti Kamina; Niki J Agnantis; Maria Bai
Journal:  Virchows Arch       Date:  2006-09-13       Impact factor: 4.064

4.  Neurilemoma of the bulbar conjunctiva.

Authors:  Koh-Ichi Ohshima; Mizue Kitada; Ichiroh Yamadori
Journal:  Jpn J Ophthalmol       Date:  2007-02-09       Impact factor: 2.447

5.  Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.

Authors:  Jens Østergaard; Jannik Boberg-Ans; Jan Ulrik Prause; Steffen Heegaard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-22       Impact factor: 3.117

6.  Risk factors for conjunctival squamous cell neoplasia: a matched case-control study.

Authors:  W Tulvatana; P Bhattarakosol; L Sansopha; W Sipiyarak; E Kowitdamrong; T Paisuntornsug; S Karnsawai
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

7.  Blue Nevi of the Ocular Surface: Clinical Characteristics, Pathologic Features, and Clinical Course.

Authors:  Ibrahim Sayed-Ahmed; Juan Carlos Murillo; Pedro Monsalve; Jan Paul Ulloa; Maria P Fernandez; James Wong; George Elgart; Anat Galor; Sander R Dubovy; Carol L Karp
Journal:  Ophthalmology       Date:  2018-03-15       Impact factor: 12.079

8.  Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma.

Authors:  Laura Asnaghi; Hind Alkatan; Alka Mahale; Maha Othman; Saeed Alwadani; Hailah Al-Hussain; Sabah Jastaneiah; Wayne Yu; Azza Maktabi; Deepak P Edward; Charles G Eberhart
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

9.  Yellow subconjunctival deposits.

Authors:  Ofira Zloto; Mordechai Rosner; Vicktoria Vishnevskia-Dai
Journal:  BMJ Case Rep       Date:  2019-08-01

Review 10.  Conjunctival melanoma and melanocytic intra-epithelial neoplasia.

Authors:  N Kenawy; S L Lake; S E Coupland; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.